Kimberly Quiring, PA
Physician Assistant · Chandler, AZNPI 1689675522
Payments from drug & device makers
Across 401 payments — averaging $21.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Argenx US, Inc.$757
- Lilly USA, LLC$724
- UCB, Inc.$652
- Teva Pharmaceuticals USA, Inc.$522
- Lundbeck LLC$446
- plus $4K from 33 others
What the payments were for
- Food & beverage$8,63299%
- Education$521%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 61 | $1,304 |
| Argenx US, Inc. | 28 | $757 |
| Lilly USA, LLC | 37 | $724 |
| UCB, Inc. | 44 | $652 |
| Teva Pharmaceuticals USA, Inc. | 21 | $522 |
| Lundbeck LLC | 23 | $446 |
| Eisai Inc. | 17 | $443 |
| Amneal Pharmaceuticals LLC | 19 | $418 |
| Acadia Pharmaceuticals Inc | 17 | $415 |
| Pfizer | 22 | $391 |
| AstraZeneca | 12 | $336 |
| Novartis | 15 | $336 |
| SK Life Science, Inc. | 10 | $244 |
| Bristol Myers Squibb | 9 | $194 |
| Otsuka America Pharmaceutical, Inc. | 7 | $144 |
| Amgen | 2 | $135 |
| Neurelis, Inc. | 5 | $117 |
| Neurocrine Biosciences, Inc. | 4 | $114 |
| Jazz Pharmaceuticals Inc. | 3 | $104 |
| CSL Behring | 4 | $101 |
| Axsome Therapeutics, Inc. | 3 | $93 |
| EMD Serono, Inc. | 3 | $88 |
| Acorda Therapeutics, Inc | 5 | $79 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $70 |
| Sumitomo Pharma America, Inc. | 4 | $63 |
| Biogen | 2 | $54 |
| Genentech USA, Inc. | 2 | $47 |
| Getinge USA Sales, LLC | 3 | $45 |
| Medtronic | 3 | $42 |
| Tonix Medicines, Inc. | 2 | $34 |
| GE HealthCare | 2 | $33 |
| Merz Pharmaceuticals, LLC | 1 | $24 |
| TG Therapeutics, Inc. | 1 | $20 |
| Azurity Pharmaceuticals, Inc. | 1 | $18 |
| Avion Pharmaceuticals | 1 | $18 |
| Corium, LLC | 1 | $16 |
| Cala Health, Inc. | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $13 |
| Alnylam Pharmaceuticals Inc. | 1 | $12 |
How this compares
$8,684 in reported general payments places this provider in the 95th percentile of 2,888 physician assistant providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 12 | $104,658 |
| UbrelvyUbrogepant | 46 | $74,338 |
| Nurtec OdtRimegepant Sulfate | 29 | $49,542 |
| Aimovig AutoinjectorErenumab-Aooe | 45 | $47,802 |
| Emgality PenGalcanezumab-Gnlm | 47 | $38,013 |
| BriviactBrivaracetam | 21 | $33,827 |
| Emgality SyringeGalcanezumab-Gnlm | 20 | $32,534 |
| Glatiramer Acetate | 12 | $17,177 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 13 | $9,153 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 176 | $8,022 |
| Gabapentin | 299 | $7,971 |
| Donepezil Hcl | 352 | $4,659 |
| Memantine Hcl | 116 | $3,269 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 52 | $2,587 |
| Pregabalin | 85 | $2,392 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $114 | $104,65812 claims |
| AbbVieUbrelvy | $1,304 | $74,33846 claims |
| PfizerNurtec Odt | $391 | $49,54229 claims |
| UCB, Inc.Briviact | $652 | $33,82721 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $418 | $77012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,888 physician assistant providers in Arizona.
Other physician assistant in Chandler
- Danielle ZitekChandler$24K
- Joan AltmanChandler$16K
- Carly HopkinsChandler$14K
- Julie SilverChandler$14K
- Emily RendaChandler$12K
- Jenna HiltonGilbert$637K
- Kara GoodingScottsdale$625K
- Ginna GranrothScottsdale$211K
- Nicole MaderaGlendale$128K
- Candace RyanGlendale$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.